CD274 and neoplasm: The KEYNOTE-199 study evaluated the efficacy of pembrolizumab monotherapy in three patient cohorts: PD-L1 positive tumor and measurable disease; PD-L1 negative tumors and measurable disease; and non-measurable metastatic bone disease regardless of PD-L1 status.